Oncodesign entered into a strategic collaboration agreement with Bristol-Myers Squibb (BMS) to discover, develop, and commercialize novel macrocyclic compounds.

The agreement is based on Oncodesign’s platform of small macrocycles, Nanocyclix®, and will also engage the advanced oncology pharmacology models at Oncodesign for cancer applications, Predict®, Chi-mice® and Pharmimage®.

The collaboration will potentially include multiple therapeutic areas and involve phenotypic cell-based approaches.